Rafet Başar

The University of Texas MD Anderson Cancer Center — United States

Immunology and Microbiology · Life Sciences

30h-index8.2kcitations158works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(106), CAR-T cell therapy research(88), Cancer Immunotherapy and Biomarkers(28), T-cell and B-cell Immunology(22), Hematopoietic Stem Cell Transplantation(13)

Publications158 total

Agent-based modeling of cellular dynamics in adoptive cell therapy
Communications Biology·2026Open Access
Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients
Transplant Infectious Disease·2026Open Access
Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients
Transplantation and Cellular Therapy·2026
Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).
Journal of Clinical Oncology·2026
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment
Cytotherapy·2025
Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.
Blood·2025Open Access
GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia
Blood·2025
CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
Blood Cancer Discovery·2025· 1 citedOpen Access
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Cancer Cell·2025· 12 citedOpen Access
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
Nature Medicine·2025· 2 citedOpen Access
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
Nature·2025· 24 citedOpen Access
Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).
Journal of Clinical Oncology·2025
Abstract 3763: Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Cancer Research·2025
Abstract 6396: CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells
Cancer Research·2025
Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells
Molecular Therapy — Methods & Clinical Development·2025· 1 citedOpen Access
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
Nature Medicine·2025· 33 cited
Agent-based modeling of cellular dynamics in adoptive cell therapy
2025Open Access
A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final report.
Journal of Clinical Oncology·2025
Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells
Cell Reports·2025· 6 citedOpen Access
343 Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells
Regular and Young Investigator Award Abstracts·2024Open Access
page 1 of 8Next →

Frequent Co-authors

Katayoun Rezvani(43), Elizabeth J. Shpall(38), May Daher(34), Pinaki P. Banerjee(32), Richard E. Champlin(25), David Marín(24), Mecit Kaplan(21), Hila Shaim(21), Ken Chen(21), Enli Liu(20), Nadima Uprety(19), Lucila Nassif Kerbauy(18), Ye Li(18), Ana Karen Nunez Cortes(17), Mayra Shanley(17), Luis Muniz-Feliciano(17), Li Li(16), Sunil Acharya(15), Hind Rafei(13), Paul Lin(13)